Amyris Inc (NASDAQ:AMRS) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 13,893,705 shares, a drop of 1.1% from the April 28th total of 14,041,318 shares. Based on an average daily volume of 6,883,547 shares, the days-to-cover ratio is currently 2.0 days.

Amyris (NASDAQ:AMRS) traded down 0.4053% during mid-day trading on Friday, reaching $0.2703. The company’s stock had a trading volume of 1,196,190 shares. The firm’s 50 day moving average is $0.44 and its 200-day moving average is $0.59. Amyris has a 12-month low of $0.24 and a 12-month high of $1.21. The company’s market cap is $75.23 million.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.04. The company had revenue of $13 million for the quarter, compared to analysts’ expectations of $32.30 million. During the same period last year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Equities analysts anticipate that Amyris will post ($0.26) earnings per share for the current fiscal year.

In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 287,706 shares of Amyris stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $0.52, for a total transaction of $149,607.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick Y. Yang bought 300,000 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The shares were acquired at an average cost of $0.29 per share, for a total transaction of $87,000.00. Following the purchase, the director now directly owns 153,000 shares in the company, valued at approximately $44,370. The disclosure for this purchase can be found here. Insiders have sold a total of 7,361,888 shares of company stock worth $3,877,084 in the last three months. 48.70% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the company. Carl Domino Inc boosted its position in Amyris by 37.4% in the first quarter. Carl Domino Inc now owns 201,925 shares of the biotechnology company’s stock worth $107,000 after buying an additional 54,925 shares during the last quarter. Geode Capital Management LLC boosted its position in Amyris by 7.5% in the first quarter. Geode Capital Management LLC now owns 588,026 shares of the biotechnology company’s stock worth $311,000 after buying an additional 41,060 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Amyris by 42.4% in the first quarter. Vanguard Group Inc. now owns 4,419,446 shares of the biotechnology company’s stock worth $2,342,000 after buying an additional 1,315,809 shares during the last quarter. 30.40% of the stock is owned by hedge funds and other institutional investors.

Several analysts recently issued reports on AMRS shares. Zacks Investment Research downgraded Amyris from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 7th. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Amyris in a research note on Tuesday.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/05/27/short-interest-in-amyris-inc-amrs-decreases-by-1-1.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

12 Month Chart for NASDAQ:AMRS

Receive News & Ratings for Amyris Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc and related companies with MarketBeat.com's FREE daily email newsletter.